The Pharmaceutical Research and Manufacturers of America (PhRMA) has added two industry veterans to its board of directors.
David Ricks, Chairman and CEO of Eli Lilly, was named chairman-elect, while Ramona Sequeira, President of Takeda Pharmaceuticals, USA assumed the role of board treasurer.
This latest round of appointments followed last month’s announcement that Giovanni Caforio, Chairman and CEO of Bristol-Myers Squibb, had assumed the role of Chairman of the board.
Ricks has served as CEO of Lilly since January 2017 and became chairman of the board of directors in June of that year.
A 20-year Lilly veteran, he previously served as president of Lilly Bio-Medicines and as president of Lilly USA, the company’s largest affiliate.
He is the president of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) and serves on the boards of Adobe and the Central Indiana Corporate Partnership.
Sequeira has served as the president of Takeda Pharmaceuticals USA since May 2015. She is a member of Takeda’s executive team. Prior to joining Takeda, she held various senior roles of increasing responsibility at Lilly.
Since Takeda’s acquisition of Shire, Sequeira leads Takeda’s US Business Unit, focused on the areas of Neuroscience, Gastrointestinal Disease, Immunology, and Haematology and Rare Disease.